Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Voyager Therapeutics, Inc. VYGR
$10.56
+$0.73 (6.92%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
423405815.00000000
-
week52high
11.49
-
week52low
4.61
-
Revenue
40907000
-
P/E TTM
-7
-
Beta
1.12664300
-
EPS
-1.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Neutral | Neutral | 03 ноя 2021 г. |
| Baird | Outperform | Neutral | 07 окт 2021 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 19 апр 2021 г. |
| Baird | Neutral | Outperform | 26 февр 2021 г. |
| Wedbush | Neutral | Outperform | 03 февр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Third Rock Ventures III, L.P. | D | 4685291 | 128642 | 01 февр 2023 г. |
| Third Rock Ventures III, L.P. | D | 4813933 | 185000 | 31 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 4998933 | 75000 | 30 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 5073933 | 50000 | 27 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 5123933 | 50000 | 25 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 5173933 | 100000 | 24 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 5273933 | 55000 | 23 янв 2023 г. |
| Third Rock Ventures III, L.P. | D | 5328933 | 100000 | 20 янв 2023 г. |
| Carter Todd Alfred | D | 35488 | 706 | 17 янв 2023 г. |
| Hesslein Robert W. | D | 112775 | 792 | 17 янв 2023 г. |
Новостная лента
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?
Zacks Investment Research
04 мая 2023 г. в 04:35
Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Voyager: Preclinical Company With Major Big Pharma Deals
Seeking Alpha
02 апр 2023 г. в 09:32
Voyager is a preclinical company with multibillion dollar big pharma deals. Its core asset is its TRACER AAV capsid delivery platform.
MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha
12 мар 2023 г. в 08:03
Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear funds in the Active ETF with over 17% gains this week. SUP peaked at +20.9% for members.
Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript
Seeking Alpha
07 мар 2023 г. в 15:09
Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Al Sandrock - Chief Executive Officer Todd Carter - Chief Scientific Officer Pete Pfreundschuh - Chief Financial Officer Allen Nunnally - Chief Business Officer Conference Call Participants Jack Allen - Baird Joon Lee - Truist Dane Leone - Raymond James Yun Zhong - BTIG Laura Chico - Wedbush Yanan Zhu - Wells Fargo Jay Olson - Oppenheimer Operator Good morning and welcome to Voyager Therapeutics 2022 Fourth Quarter and Year End Conference Call. All participants are now in listen-only mode.
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
07 мар 2023 г. в 09:47
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?